Hikma has agreed to acquire 100% of the share capital of Medlac Pharma Italy Co. Ltd. (Medlac), an Italian-Vietnamese joint venture founded in 2008. Medlac Pharma makes injectables from a manufacturing site in Vietnam.
The acquisition includes the injectable facility, adjacent vacant land, Medlac’s product portfolio of 23 injectable products, its pipeline and all employees.
Hikma is a global manufacturer of generic injectables. The company operates in the US, the Middle East and North Africa, and Europe.
This acquisition, Hikma said, provides a foothold in Vietnam, one of the most dynamic emerging markets in Asia.
Driven by a growing population, government healthcare reforms and strong economic development, Vietnam has been the fastest growing pharmaceutical market in South East Asia in recent years and this fast-paced growth is expected to continue.
Medlac operates an injectables facility in Hanoi, Vietnam. Since it commenced operations in 2012, it has built a reputation as a high-quality manufacturer in the areas of anti-infectives and cardiovascular.